6.6 Drugs affecting bone metabolism
6.6 Drugs affecting bone metabolism
Management of Patients Receiving Treatment with Bisphosphonates
Treatment of Osteonecrosis of the Jaw |
RED Pentoxyfylline tablets (off licence use, consultant use only) |
RED Vitamin E tablets (off licence use, consultant use only) |
|
Osteoporosis occurs most commonly in postmenopausal women and in those taking long-term oral corticosteroids |
(glucocorticosteroids). Other risk factors for osteoporosis include low body weight, cigarette smoking, excess alcohol intake, lack |
of physical activity, family history of osteoporosis, and early menopause.
|
|
Those at risk of osteoporosis should maintain an adequate intake of calcium and | vitamin D and any deficiency should be corrected by increasing dietary intake or taking supplements. | |
|
See section 9.5.1.1 for calcium and 9.6.4 for vitamin D replacement, and section 6.4.1 for raloxifene. |
|
NICE TA265 - Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours. |
Denosumab is recommended as an option for preventing skeletal-related events (pathological fracture, radiation to bone, spinal |
cord compression or surgery to bone) in adults with bone metastases from breast cancer and from solid tumours other than |
prostate if: |
> bisphosphonates would otherwise be prescribed and |
> the manufacturer provides denosumab with the discount agreed in the patient access scheme. |
|
RED Denosumab injection pre-filled syringe 120mg (XGEVA®) |
|
|
|
BACK to main page |
|
All material in this section is aimed at health care professionals, but is information currently held in the public domain, members of the | public seeking advice on medicine-related matters are advised to speak with their GP, pharmacist, nurse or contact NHS111 Service | Email: info.elmmb@nhs.net | Copyright© 2016 - 2023 East Lancashire Medicines Management Board | All rights reserved. Disclaimer/Terms and conditions | |
|
|